abstract: UNASSIGNED: OBJECT Symptomatic pediatric @entity2 ( @entity2 ) is most often treated with @entity5 ( @entity5 ), but controversy exists over whether the dura needs to be opened during @entity5 . While dural opening as a part of @entity5 has been suggested to result in a higher rate of resolution of @entity1 , it has also been shown to lead to more frequent complications. In this paper, the authors present the largest reported series of outcomes after @entity5 without dural opening surgery, as well as identify risk factors for recurrence. METHODS The authors performed a retrospective review of 156 consecutive pediatric @entity0 in whom the senior authors performed @entity5 without dural opening from 2003 to 2013. @entity0 demographics, clinical symptoms and signs, radiographic findings, intraoperative ultrasound results, and neuromonitoring findings were reviewed. Univariate and multivariate regression analyses were performed to determine risk factors for recurrence of symptoms and the need for reoperation. RESULTS Over 90% of @entity0 had a good clinical outcome, with improvement or resolution of their symptoms at last follow-up (mean 32 months). There were no major complications. The mean length of hospital stay was 2.0 days. In a multivariate regression model, partial @entity3 laminectomy was an independent risk factor associated with reoperation (p = 0.037). Motor weakness on presentation was also associated with reoperation but only with trend-level significance (p = 0.075). No @entity0 with < 8 mm of @entity4 required reoperation. CONCLUSIONS The vast majority (> 90%) of @entity0 with symptomatic @entity2 will have improvement or resolution of symptoms after a @entity5 without dural opening. A non-dural opening approach avoids major complications. While no @entity0 with @entity4 < 8 mm required reoperation, @entity0 with @entity4 at or below @entity3 have a higher risk for failure when this approach is used.

title: Outcomes after suboccipital decompression without dural opening in XXXX with @entity2 .

answer: @entity0


abstract: UNASSIGNED: This study evaluated the effects of electroacupuncture (EA) on endothelial function and endothelial progenitor cells (EPC) in @entity0 with @entity2 . In a randomized, placebo-controlled, crossover study, 20 @entity0 with @entity2 were randomized into two treatment groups: EA or placebo. Before and after each intervention, pulse amplitude tonometry (PAT) was used to assess endothelial function and peripheral blood was analyzed for the number of EPCs. Circulating EPCs were quantified by flow cytometry as @entity5 (low) @entity6 (+) KDR2(+) cells. Plasma @entity1 ( @entity1 ) and @entity4 levels were measured. Seven days later, crossover was performed on each group, with each group receiving the other treatment using the same protocol. The PAT @entity3 ratio ranged from 1.57  0.41 to 2.04  0.51 after EA, representing a significant improvement (p=0.002); however, there was no improvement in the placebo group (p=0.48). Circulating EPCs, as measured by flow cytometry, increased to 110.6    74.3/100ul in the EA group (p=0.001) but did not change in the placebo group (45.9    35.3/100ul, p=0.08). The increases in the number  of EPCs and the PAT ratio after treatment were correlated (r=0.78, p<0.001). Plasma @entity1 levels increased with EA compared to baseline (261.2  34.0 vs. 334.9  80.5 pg/mL, p=0.003). The number of circulating EPCs was positively correlated with plasma levels of @entity1 (r=0.50, p=0.02). In conclusion, EA induced improvement of EPC levels and the PAT ratio in @entity0 with @entity2 . This article is protected by copyright. All rights reserved.

title: Effects of Electroacupuncture on Endothelial Function and Circulating Endothelial Progenitor Cells in @entity0 with XXXX .

answer: @entity2


abstract: UNASSIGNED: This study evaluated the effects of electroacupuncture (EA) on endothelial function and endothelial progenitor cells (EPC) in @entity0 with @entity2 . In a randomized, placebo-controlled, crossover study, 20 @entity0 with @entity2 were randomized into two treatment groups: EA or placebo. Before and after each intervention, pulse amplitude tonometry (PAT) was used to assess endothelial function and peripheral blood was analyzed for the number of EPCs. Circulating EPCs were quantified by flow cytometry as @entity5 (low) @entity6 (+) KDR2(+) cells. Plasma @entity1 ( @entity1 ) and @entity4 levels were measured. Seven days later, crossover was performed on each group, with each group receiving the other treatment using the same protocol. The PAT @entity3 ratio ranged from 1.57  0.41 to 2.04  0.51 after EA, representing a significant improvement (p=0.002); however, there was no improvement in the placebo group (p=0.48). Circulating EPCs, as measured by flow cytometry, increased to 110.6    74.3/100ul in the EA group (p=0.001) but did not change in the placebo group (45.9    35.3/100ul, p=0.08). The increases in the number  of EPCs and the PAT ratio after treatment were correlated (r=0.78, p<0.001). Plasma @entity1 levels increased with EA compared to baseline (261.2  34.0 vs. 334.9  80.5 pg/mL, p=0.003). The number of circulating EPCs was positively correlated with plasma levels of @entity1 (r=0.50, p=0.02). In conclusion, EA induced improvement of EPC levels and the PAT ratio in @entity0 with @entity2 . This article is protected by copyright. All rights reserved.

title: Effects of Electroacupuncture on Endothelial Function and Circulating Endothelial Progenitor Cells in XXXX with @entity2 .

answer: @entity0


abstract: The present study demonstrates a major remodeling of the nuclear envelope and its underlying lamina during @entity0 preimplantation development. Up to the onset of major embryonic genome activation (MGA) at the 8-cell stage nuclei showed a non-uniform distribution of nuclear pore complexes (NPCs). NPCs were exclusively present at sites where DNA contacted the nuclear lamina. Extended regions of the lamina, which were not contacted by DNA, lacked NPCs. In post-MGA nuclei the whole lamina was contacted rather uniformly by DNA. Accordingly, NPCs became uniformly distributed throughout the entire nuclear envelope. These findings shed new light on the conditions which control the integration of NPCs into the nuclear envelope. The switch from maternal to embryonic production of mRNAs was accompanied by @entity1 covered with NPCs, which may serve the increased demands of mRNA export and protein import. Other invaginations, as well as interior nuclear segments and vesicles without contact to the nuclear envelope, were exclusively positive for lamin B. Since the abundance of these invaginations and vesicles increased in concert with a massive nuclear volume reduction, we suggest that they reflect a mechanism for fitting the nuclear envelope and its lamina to a shrinking nuclear size during @entity0 preimplantation development. In addition, a deposit of extranuclear clusters of @entity2 (a marker for NPCs) without associated lamin B was frequently observed from the zygote stage up to MGA. Corresponding RNA-Seq data revealed deposits of spliced, maternally provided @entity2 mRNA and little unspliced, newly synthesized RNA prior to MGA, which increased strongly at the initiation of embryonic expression of @entity2 at MGA.

title: Remodeling of the Nuclear Envelope and Lamina during XXXX Preimplantation Development and Its Functional Implications.

answer: @entity0


abstract: Three hundred eighty-seven pregnancies (295 @entity0 ) complicated by maternal @entity2 , managed at the National Maternity Hospital, Dublin, Ireland, during the years 1969 to 1978, were reviewed. The incidence was 0.5%. Three hundred twenty-three (83.5%) were of rheumatic origin, 52 (13.4%) were congenital, and the remaining 12 (3.1%) were a miscellaneous group and included cases of @entity6 and @entity3 . There were two maternal @entity1 --one from @entity2 and one from postpartum suicide, unrelated to mild @entity7 . The perinatal mortality rate was 3.3%. Five pregnancies (three @entity0 ) were complicated by surgically uncorrected @entity2 . One of the maternal @entity1 and three of the perinatal @entity1 occurred in this group. There were 38 episodes of @entity4 (38 @entity0 ) in cases of @entity7 . The New York Heart Association grading was grade 1 in 15 (39%) of these before the onset of failure. Prophylactic antibiotics were not used and @entity5 did not occur. Therapeutic abortion was not practiced and a conservative approach was adopted in obstetric intervention and in all drug therapy.

title: Pregnancy complicated by maternal XXXX at the National Maternity Hospital, Dublin, Ireland, 1969 to 1978.

answer: @entity2


abstract: UNASSIGNED: In Y-stenting, stabilization of the first stent may be problematic as in some cases it migrates during second stent insertion. This report evaluates the safety and effectiveness of the technique and presents the long-term results of hybrid, Y-configured, dual stent-assisted coil embolization in the treatment of wide-necked bifurcation @entity4 . We retrospectively evaluated the @entity0 treated endovascularly due to @entity3 . Twenty @entity0 treated with hybrid Y-stent-assisted coil embolization were enrolled in the study. In hybrid stenting, an open-cell intracranial stent (Neuroform) was used as a first stent to prevent stent migration. A closed-cell stent (Enterprise or Acclino) was used as a second stent and the @entity4 was embolized with coils between the stent struts. In all @entity0 , hybrid Y-stenting and coil embolization were accomplished successfully. No stent migration occurred. Clinically, neither symptomatic @entity1 nor @entity2 was seen. Of 20 wide-necked bifurcation @entity4 , nine were at the basilar tip, while seven were at the middle cerebral artery and three at the anterior communicating artery. In one @entity0 , the @entity4 was at the A2-3 junction of the anterior cerebral artery. One of the @entity0 had a @entity5 . The mean angiographic follow-up was 25.6 months. No in-stent @entity6 was seen in any of the @entity0 and recanalization in only one. Hybrid, Y-configured, dual stent-assisted coil embolization is a safe and effective method in the treatment of wide-necked bifurcation @entity4 to prevent stent migration and @entity4 recanalization, and is a viable alternative to microsurgery.

title: Hybrid, Y-configured, dual stent-assisted coil embolization in the treatment of wide-necked bifurcation XXXX .

answer: @entity4


abstract: OBJECTIVES: To determine whether the @entity1 necrosis factor a inhibitor etanercept is well tolerated and obtain preliminary data on its safety in @entity2 . METHODS: In a double-blind study, @entity0 with mild to moderate @entity2 were randomized (1:1) to subcutaneous etanercept (50 mg) once weekly or identical placebo over a 24-week period. Tolerability and safety of this medication was recorded including secondary outcomes of cognition, global function, behavior, and systemic cytokine levels at baseline, 12 weeks, 24 weeks, and following a 4-week washout period. This trial is registered with EudraCT (2009-013400-31) and ClinicalTrials.gov (NCT01068353). RESULTS: Forty-one @entity0 (mean age 72.4 years; 61% @entity0 ) were randomized to etanercept (n = 20) or placebo (n = 21). Etanercept was well tolerated; 90% of @entity0 (18/20) completed the study compared with 71% (15/21) in the placebo group. Although @entity3 were more common in the etanercept group, there were no serious adverse events or new safety concerns. While there were some interesting trends that favored etanercept, there were no statistically significant changes in cognition, behavior, or global function. CONCLUSIONS: This study showed that subcutaneous etanercept (50 mg/wk) was well tolerated in this small group of @entity0 with @entity2 , but a larger more heterogeneous group needs to be tested before recommending its use for broader groups of @entity0 . CLASSIFICATION OF EVIDENCE: This study shows Class I evidence that weekly subcutaneous etanercept is well tolerated in @entity2 .

title: Etanercept in XXXX : A randomized, placebo-controlled, double-blind, phase 2 trial.

answer: @entity2


abstract: BACKGROUND: @entity5 ( @entity5 ) is an excessive fibrotic response of the peritoneum that may occur after long-term @entity2 ( @entity2 ). The underlying pathophysiology is poorly understood, but involvement of peritoneal inflammatory T helper 1 cells may be pivotal. METHODS: Soluble @entity4 (sCD25) concentration was measured as a marker for T-cell activation in serum and ascites from @entity5 @entity0 and various control @entity0 groups. Peritoneal biopsies were stained for the presence of T cells, and T cells isolated from ascites of @entity5 @entity0 were characterized in detail for differentiation status and cytokine expression. RESULTS: Serum sCD25 concentrations are significantly and specifically increased in @entity5 @entity0 compared with haemodialysis, @entity2 and predialysis @entity0 . Peritoneal effluent of stable @entity2 @entity0 contains very low levels of sCD25, while sCD25 levels in ascites of @entity5 @entity0 are high and indicative of local production. In the years preceding the diagnosis of @entity5 , the serum sCD25 concentrations increased while remaining at stable levels in control @entity2 @entity0 . The peritoneum and ascites of @entity5 @entity0 showed a significant influx of T cells with relatively increased numbers of @entity3 (+) T cells. These T cells were fully differentiated and displayed a T helper 1 cell type with a pro-inflammatory cytokine profile. CONCLUSIONS: Increased serum sCD25 concentrations and peritoneal lymphocytosis in @entity5 @entity0 indicate the involvement of activated T cells in the pathophysiology of excessive @entity1 .

title: XXXX is associated with T-cell activation.

answer: @entity5


abstract: INTRODUCTION: We hypothesized that treating @entity3 with cast only or closed reduction and cast is associated with high malunion risk and that the risk is higher in @entity0 with low @entity1 ( @entity1 ). MATERIALS AND METHODS: We prospectively studied 130 @entity0 aged 40  years or older with @entity3 treated with cast only (87 @entity0 ) or closed reduction and cast (43 @entity0 ). Radiographs were obtained before treatment, after reduction (in the closed reduction group), and at 1  year. We measured calcaneal @entity1 with DXA scanner and calculated T scores. We calculated radiological changes from baseline (initial radiographs in cast only and post-reduction radiographs in closed reduction @entity0 ) to 1  year. We assessed the relationship between @entity1 status (normal, @entity4 or @entity2 ) and baseline-to-1-year worsening in volar tilt, ulnar variance, and radial inclination with analysis of covariance adjusting for baseline radiological values. We used receiver operating characteristic (ROC) analysis to determine the ability of T scores to distinguish @entity0 with severe malunion (dorsal tilt >25   and/or ulnar variance >= 5  mm) from those with less severe or no malunion. RESULTS: In both treatment groups, baseline radiological variables had deteriorated at 1  year, more in the closed reduction group. Compared to @entity0 with normal @entity1 , those with @entity2 had significantly greater worsening in volar tilt and radial inclination but did not differ in ulnar variance worsening. Severe malunion was found in 34 @entity3 (26  %, 15 in cast only group); T scores had a modest ability in distinguishing severe malunion (area under ROC curve 0.67, 95  % CI 0.56-0.78, p  =  0.003). CONCLUSIONS: Closed reduction and cast is not an effective treatment for @entity3 if radiological graphic outcomes are considered. There is a higher risk of malunion involving dorsal and radial tilt in @entity0 with @entity2 . Calcaneal @entity1 measurement may have some benefit in predicting the risk of severe malunion.

title: Cast-treated XXXX : a prospective cohort study of radiological outcomes and their association with impaired calcaneal @entity1 .

answer: @entity3


abstract: INTRODUCTION: We hypothesized that treating @entity3 with cast only or closed reduction and cast is associated with high malunion risk and that the risk is higher in @entity0 with low @entity1 ( @entity1 ). MATERIALS AND METHODS: We prospectively studied 130 @entity0 aged 40  years or older with @entity3 treated with cast only (87 @entity0 ) or closed reduction and cast (43 @entity0 ). Radiographs were obtained before treatment, after reduction (in the closed reduction group), and at 1  year. We measured calcaneal @entity1 with DXA scanner and calculated T scores. We calculated radiological changes from baseline (initial radiographs in cast only and post-reduction radiographs in closed reduction @entity0 ) to 1  year. We assessed the relationship between @entity1 status (normal, @entity4 or @entity2 ) and baseline-to-1-year worsening in volar tilt, ulnar variance, and radial inclination with analysis of covariance adjusting for baseline radiological values. We used receiver operating characteristic (ROC) analysis to determine the ability of T scores to distinguish @entity0 with severe malunion (dorsal tilt >25   and/or ulnar variance >= 5  mm) from those with less severe or no malunion. RESULTS: In both treatment groups, baseline radiological variables had deteriorated at 1  year, more in the closed reduction group. Compared to @entity0 with normal @entity1 , those with @entity2 had significantly greater worsening in volar tilt and radial inclination but did not differ in ulnar variance worsening. Severe malunion was found in 34 @entity3 (26  %, 15 in cast only group); T scores had a modest ability in distinguishing severe malunion (area under ROC curve 0.67, 95  % CI 0.56-0.78, p  =  0.003). CONCLUSIONS: Closed reduction and cast is not an effective treatment for @entity3 if radiological graphic outcomes are considered. There is a higher risk of malunion involving dorsal and radial tilt in @entity0 with @entity2 . Calcaneal @entity1 measurement may have some benefit in predicting the risk of severe malunion.

title: Cast-treated @entity3 : a prospective cohort study of radiological outcomes and their association with impaired calcaneal XXXX .

answer: @entity1


abstract: AIMS: Left atrial appendage (LAA) is the source of thrombi in up to 90% of @entity0 with non-valvular @entity5 ( @entity5 ). Catheter ablation (CA) is an effective treatment for symptomatic @entity5 and, in selected cases, LAA occlusion devices have been introduced as an alternative to oral anticoagulants (OACs). The safety and feasibility of combining CA and percutaneous LAA closure (LAAC) are unknown. METHODS AND RESULTS: @entity0 with symptomatic drug-refractory @entity5 , CHADS2 score of >= 1, and CHA2DS2-VASc score >= 2 were included. Catheter ablation consisted in pulmonary vein isolation with or without roof line with radiofrequency and LAA was occluded with the Watchman or @entity2 ( @entity2 ) devices guided by angiography and transoesophageal echocardiography. A total of 35 @entity0 were included (71% male; 70 years). Median score was 3 on both CHA2DS2-VASc and HAS-BLED, 9% had prior @entity1 under OAC, and 48% had @entity3 complications. Successful CA and device implantation were achieved in 97% of cases. The Watchman device was used in 29 @entity0 and @entity2 in 6 @entity0 . Periprocedural complications included three cases of @entity6 . At 3 months, all @entity0 met the criteria for successful sealing of the LAA. After a mean follow-up of 13 months (3-75), 78% of @entity0 were free of @entity4 recurrences and OAC was withheld in 97% of @entity0 . CONCLUSIONS: The combination of CA and percutaneous LAAC in a single procedure is technically feasible in @entity0 with symptomatic drug-refractory @entity5 , high risk of @entity1 , and contraindications to OACs, although it is associated with a significant risk of major complications.

title: Combined catheter ablation and left XXXX as a hybrid procedure for the treatment of @entity5 .

answer: @entity5


abstract: AIMS: Left atrial appendage (LAA) is the source of thrombi in up to 90% of @entity0 with non-valvular @entity5 ( @entity5 ). Catheter ablation (CA) is an effective treatment for symptomatic @entity5 and, in selected cases, LAA occlusion devices have been introduced as an alternative to oral anticoagulants (OACs). The safety and feasibility of combining CA and percutaneous LAA closure (LAAC) are unknown. METHODS AND RESULTS: @entity0 with symptomatic drug-refractory @entity5 , CHADS2 score of >= 1, and CHA2DS2-VASc score >= 2 were included. Catheter ablation consisted in pulmonary vein isolation with or without roof line with radiofrequency and LAA was occluded with the Watchman or @entity2 ( @entity2 ) devices guided by angiography and transoesophageal echocardiography. A total of 35 @entity0 were included (71% male; 70 years). Median score was 3 on both CHA2DS2-VASc and HAS-BLED, 9% had prior @entity1 under OAC, and 48% had @entity3 complications. Successful CA and device implantation were achieved in 97% of cases. The Watchman device was used in 29 @entity0 and @entity2 in 6 @entity0 . Periprocedural complications included three cases of @entity6 . At 3 months, all @entity0 met the criteria for successful sealing of the LAA. After a mean follow-up of 13 months (3-75), 78% of @entity0 were free of @entity4 recurrences and OAC was withheld in 97% of @entity0 . CONCLUSIONS: The combination of CA and percutaneous LAAC in a single procedure is technically feasible in @entity0 with symptomatic drug-refractory @entity5 , high risk of @entity1 , and contraindications to OACs, although it is associated with a significant risk of major complications.

title: Combined catheter ablation and left @entity5 as a hybrid procedure for the treatment of XXXX .

answer: @entity5


abstract: OBJECTIVE: Whereas uncomplicated acute type B aortic dissections are often medically managed with good outcomes, a subset develop subacute or chronic @entity1 . We hypothesized that @entity4 ( @entity4 ) simulations may be useful in identifying @entity0 at risk for this complication. METHODS: @entity0 with acute type B dissection complicated by rapidly expanding @entity3 (N  = 7) were compared with @entity0 with stable aortic diameters (N  = 7). Three-dimensional @entity0 -specific dissection geometries were generated from computed tomography angiography and used in @entity4 simulations of pulsatile blood flow. Hemodynamic parameters including false lumen flow and wall shear stress were compared. RESULTS: @entity0 with rapid @entity2 had a growth rate of 5.3     2.7  mm/mo compared with those with stable aortic diameters, who had rates of 0.2     0.02  mm/mo. Groups did not differ in initial aortic diameter (36.1     2.9 vs 34.4     3.6  mm; P  = .122) or false lumen size (22.6     2.9 vs 20.2     4.5  mm; P  = .224). In @entity0 with rapidly expanding @entity2 , a greater percentage of total flow passed through the false lumen (78.3%     9.3% vs 56.3%     11.8%; P  = .016). The time-averaged wall shear stress on the aortic wall was also significantly higher (12.6     3.7 vs 7.4     2.8  Pa; P  = .028). CONCLUSIONS: Hemodynamic parameters derived from @entity4 simulations of acute type B aortic dissections were significantly different in dissections complicated by @entity2 formation. Thus, @entity4 may assist in predicting which @entity0 may benefit from early stent grafting.

title: Use of @entity4 studies in predicting XXXX of acute type B  aortic dissections.

answer: @entity2


abstract: OBJECTIVE: Whereas uncomplicated acute type B aortic dissections are often medically managed with good outcomes, a subset develop subacute or chronic @entity1 . We hypothesized that @entity4 ( @entity4 ) simulations may be useful in identifying @entity0 at risk for this complication. METHODS: @entity0 with acute type B dissection complicated by rapidly expanding @entity3 (N  = 7) were compared with @entity0 with stable aortic diameters (N  = 7). Three-dimensional @entity0 -specific dissection geometries were generated from computed tomography angiography and used in @entity4 simulations of pulsatile blood flow. Hemodynamic parameters including false lumen flow and wall shear stress were compared. RESULTS: @entity0 with rapid @entity2 had a growth rate of 5.3     2.7  mm/mo compared with those with stable aortic diameters, who had rates of 0.2     0.02  mm/mo. Groups did not differ in initial aortic diameter (36.1     2.9 vs 34.4     3.6  mm; P  = .122) or false lumen size (22.6     2.9 vs 20.2     4.5  mm; P  = .224). In @entity0 with rapidly expanding @entity2 , a greater percentage of total flow passed through the false lumen (78.3%     9.3% vs 56.3%     11.8%; P  = .016). The time-averaged wall shear stress on the aortic wall was also significantly higher (12.6     3.7 vs 7.4     2.8  Pa; P  = .028). CONCLUSIONS: Hemodynamic parameters derived from @entity4 simulations of acute type B aortic dissections were significantly different in dissections complicated by @entity2 formation. Thus, @entity4 may assist in predicting which @entity0 may benefit from early stent grafting.

title: Use of XXXX studies in predicting @entity2 of acute type B  aortic dissections.

answer: @entity4


abstract: From 1972-1982 149 pathological @entity3 in 91 @entity1 were treated. 134 of these were caused by @entity2 . With 78% metastases were the most common cause for @entity3 . 59% of the @entity1 were @entity1 . The most frequent @entity3 localisation was the femur followed by ribs and humerus. 62% of the @entity3 but 100% of the leg @entity3 were treated operatively. The best functional results were achieved after compound osteo-synthesis. The mean survival time of the @entity1 was 10.7 months. The one year survival rate was 24.6% and the two year survival rate was 9.2%. The best survival rates were observed in @entity1 , @entity1 with @entity0 metastases, femur shaft- or subtrochanteric @entity3 . The lowest survival rate was found in male @entity1 , @entity1 with unknown primary @entity2 and @entity4 .

title: [Functional results following conservative and surgical therapy of pathologic XXXX in @entity2 ].

answer: @entity3


abstract: From 1972-1982 149 pathological @entity3 in 91 @entity1 were treated. 134 of these were caused by @entity2 . With 78% metastases were the most common cause for @entity3 . 59% of the @entity1 were @entity1 . The most frequent @entity3 localisation was the femur followed by ribs and humerus. 62% of the @entity3 but 100% of the leg @entity3 were treated operatively. The best functional results were achieved after compound osteo-synthesis. The mean survival time of the @entity1 was 10.7 months. The one year survival rate was 24.6% and the two year survival rate was 9.2%. The best survival rates were observed in @entity1 , @entity1 with @entity0 metastases, femur shaft- or subtrochanteric @entity3 . The lowest survival rate was found in male @entity1 , @entity1 with unknown primary @entity2 and @entity4 .

title: [Functional results following conservative and surgical therapy of pathologic @entity3 in XXXX ].

answer: @entity2


abstract: PURPOSE: To investigate the efficacy and technical applicability of cavitron ultrasonic surgical aspirator (CUSA)-driven zero- @entity2 open partial nephrectomy in @entity0 with @entity5 . MATERIALS AND METHODS: We prospectively collected data of 13 consecutive @entity0 , who underwent open partial nephrectomy under non-ischemic conditions. @entity1 resection was done using an ultrasonic device (CUSA/SONOCA 300). @entity1 characteristics, perioperative, and postoperative variables were evaluated. RESULTS: The median age was 60.0  years (range 40-76); body mass index 28.0  kg/m(2) (range 22.9-43.3); @entity1 size 37.0  mm (range 11-110  mm). @entity0 were stratified according to the PADUA score into low- (score 6-7; n  -  4), intermediate- (score 8-9; n  -  5), and high-risk (score of >10; n  -  4) groups, and the median score was 9.0 (range 6-13; SD +2.3). The vast majority of @entity5 were diagnosed incidentally (n  -  11; 84.6  %). Median operative time was 175  min (55-270  min); median time of @entity1 extirpation was 12  min (6-25  min); and median @entity3 was 250  ml. Serum @entity6 , glomerular filtration rate, and hemoglobin were nearly unaltered before and after surgery in 11 cases (84.6  %). Three @entity0 received a blood transfusion (Clavien-Dindo Grade II); one had Grade IIIa complication (insertion of double J stent without general anesthesia); and three had @entity4 (insertion of double J under general anesthesia). CONCLUSIONS: The ultrasonic device demonstrated acceptable hemostatic and resection properties during open partial nephrectomy without @entity2 . Our series showed promising perioperative and postoperative outcomes that may help in maximizing preservation of renal function in partial nephrectomy candidates.

title: Partial nephrectomy driven by cavitron ultrasonic surgical aspirator under zero XXXX : a pilot study.

answer: @entity2


abstract: UNASSIGNED: Furfural and @entity2 from lignocellulosic hydrolysates are the prevalent inhibitors to @entity3 during cellulosic @entity1 production. Developing a strain tolerant to furfural or @entity2 inhibitors is difficul by using rational engineering strategies due to poor understanding of their underlying molecular mechanisms. In this study, strategy of adaptive laboratory evolution (ALE) was used for development of a furfural and @entity2 -tolerant strain. After three round evolution, four evolved mutants (ZMA7-2, ZMA7-3, ZMF3-2, and ZMF3-3) that showed higher growth capacity were successfully obtained via ALE method. Based on the results of profiling of cell growth, @entity0 utilization, @entity1 yield, and activity of key enzymes, two desired strains, ZMA7-2 and ZMF3-3, were achieved, which showed higher tolerance under 7  g/l @entity2 and 3  g/l furfural stress condition. Especially, it is the first report of @entity3 that could tolerate higher furfural. The best strain, @entity3 ZMF3-3, has showed 94.84  % theoretical @entity1 yield under 3-g/l furfural stress condition, and the theoretical @entity1 yield of ZM4 is only 9.89  %. Our study also demonstrated that ALE method might also be used as a powerful metabolic engineering tool for metabolic engineering in @entity3 . Furthermore, the two best strains could be used as novel host for further metabolic engineering in cellulosic @entity1 or future biorefinery. Importantly, the two strains may also be used as novel-tolerant model organisms for the genetic mechanism on the "omics" level, which will provide some useful information for inverse metabolic engineering.

title: Adaptive laboratory evolution of ethanologenic XXXX tolerant to furfural and @entity2 inhibitors.

answer: @entity3


abstract: UNASSIGNED: Furfural and @entity2 from lignocellulosic hydrolysates are the prevalent inhibitors to @entity3 during cellulosic @entity1 production. Developing a strain tolerant to furfural or @entity2 inhibitors is difficul by using rational engineering strategies due to poor understanding of their underlying molecular mechanisms. In this study, strategy of adaptive laboratory evolution (ALE) was used for development of a furfural and @entity2 -tolerant strain. After three round evolution, four evolved mutants (ZMA7-2, ZMA7-3, ZMF3-2, and ZMF3-3) that showed higher growth capacity were successfully obtained via ALE method. Based on the results of profiling of cell growth, @entity0 utilization, @entity1 yield, and activity of key enzymes, two desired strains, ZMA7-2 and ZMF3-3, were achieved, which showed higher tolerance under 7  g/l @entity2 and 3  g/l furfural stress condition. Especially, it is the first report of @entity3 that could tolerate higher furfural. The best strain, @entity3 ZMF3-3, has showed 94.84  % theoretical @entity1 yield under 3-g/l furfural stress condition, and the theoretical @entity1 yield of ZM4 is only 9.89  %. Our study also demonstrated that ALE method might also be used as a powerful metabolic engineering tool for metabolic engineering in @entity3 . Furthermore, the two best strains could be used as novel host for further metabolic engineering in cellulosic @entity1 or future biorefinery. Importantly, the two strains may also be used as novel-tolerant model organisms for the genetic mechanism on the "omics" level, which will provide some useful information for inverse metabolic engineering.

title: Adaptive laboratory evolution of ethanologenic @entity3 tolerant to furfural and XXXX inhibitors.

answer: @entity2


abstract: The main aim of the present study was to gain insight into the stability of an anaerobic digestion process suffering from exposure to antibiotics and the methanogenic inhibitor @entity6 ( @entity5 ). For this purpose, eleven antibiotics and @entity5 were investigated with regard to the degradation of volatile @entity3 (VFAs), methanogenesis, and impact on the microbial community structure. Only @entity4 , @entity1 , @entity2 , and @entity5 showed complete inhibitions of VFA degradations. This points to distinct interferences with important trophic degradation cascades. Based upon DGGE and sequencing approaches, Methanosarcina spp. were severely influenced by the treatments while hydrogenotrophic methanogens were less affected. Interestingly, @entity5 and @entity4 inhibited the degradation of @entity0 while only @entity5 inhibited methanogenesis completely. It seems that Methanosarcina spp. were mandatory for the degradation of @entity0 at high rates. The present results highly emphasize the detrimental effects of antimicrobial compounds with the potential to significantly inhibit the anaerobic digestion.

title: Impact of several antibiotics and XXXX on the volatile fatty acid degradation, methanogenesis and community structure during thermophilic anaerobic digestion.

answer: @entity6


abstract: The clinical picture, radiological findings and treatment of 22 @entity0 with @entity6 and @entity2 are described. This lesion, untreated, may result in damage to the spinal cord, paresis or @entity3 . @entity1 , present in 13 of 22 @entity0 , was often aggravated by working with the head in forward flexion. Paresthesias were present in six @entity0 . The spine of the @entity5 was often prominent. In three @entity0 there was objective evidence of @entity4 with sensory and/or pyramidal signs. In eight the lesion was asymptomatic and discovered by routine lateral radiography in flexion, the position of maximum subluxation.Conservative treatment involved the continuous use of a cervical collar to limit neck flexion. This usually relieved subjective symptoms including @entity1 . Successful surgical fixation was performed in two individuals. Surgical indications included @entity4 or severe symptoms unrelieved by a collar.

title: XXXX and its clinical presentation.

answer: @entity2


abstract: UNASSIGNED: Epithelioid @entity6 ( @entity6 ) can easily be confused with @entity4 ( @entity3 ). In serous effusion, @entity8 is shown to be useful in the diagnosis of @entity5 vs @entity3 . @entity11 is reported to be overexpressed in epithelioid @entity5 and absent in @entity0 airway epithelium. The aim was to assess the value of @entity8 and @entity9 compared to that of BerEp4 and @entity7 ( @entity7 ) in differentiating lung ACA from epithelioid @entity6 and to examine the expression of @entity11 in these @entity1 . The expression of @entity8 , @entity9 , @entity11 , BerEp4, and @entity7 was examined by immunohistochemistry in a total of 62 @entity0 specimen including 28 epithelioid MPMs and 34 @entity3 of the lung. In lung ACA, @entity9 was strongly expressed in all 34 (100%) specimens followed by @entity8 in 33 (97%) of 34. BerEp4 was expressed in 32 (94.1%) of 34. @entity7 reacted for only 20 (58.82%) of 34 cases of lung ACA. In @entity6 specimens, the expression of @entity10 as well as that of @entity7 was completely absent. In contrast, BerEp4 was focally expressed in 5 (17.85%) of 28 cases of epithelioid @entity6 . @entity11 was strongly expressed in 53% pf epithelioid MPMs but also in 50% of lung @entity3 . Its expression was moderate in normal pleura and limited in normal lung. @entity8 and @entity9 appear to be the best performing @entity2 markers in discriminating lung ACA from @entity5 compared with BerEp4 and @entity7 . There is no differential expression of @entity11 between the 2 pathologies. However, the limited @entity11 expression in normal tissues and high expression in @entity1 make it an attractive candidate for @entity1 therapy.

title: XXXX , 4, and 15 expression in solid tumors of lung adenocarcinoma versus @entity6 .

answer: @entity8


abstract: UNASSIGNED: Epithelioid @entity6 ( @entity6 ) can easily be confused with @entity4 ( @entity3 ). In serous effusion, @entity8 is shown to be useful in the diagnosis of @entity5 vs @entity3 . @entity11 is reported to be overexpressed in epithelioid @entity5 and absent in @entity0 airway epithelium. The aim was to assess the value of @entity8 and @entity9 compared to that of BerEp4 and @entity7 ( @entity7 ) in differentiating lung ACA from epithelioid @entity6 and to examine the expression of @entity11 in these @entity1 . The expression of @entity8 , @entity9 , @entity11 , BerEp4, and @entity7 was examined by immunohistochemistry in a total of 62 @entity0 specimen including 28 epithelioid MPMs and 34 @entity3 of the lung. In lung ACA, @entity9 was strongly expressed in all 34 (100%) specimens followed by @entity8 in 33 (97%) of 34. BerEp4 was expressed in 32 (94.1%) of 34. @entity7 reacted for only 20 (58.82%) of 34 cases of lung ACA. In @entity6 specimens, the expression of @entity10 as well as that of @entity7 was completely absent. In contrast, BerEp4 was focally expressed in 5 (17.85%) of 28 cases of epithelioid @entity6 . @entity11 was strongly expressed in 53% pf epithelioid MPMs but also in 50% of lung @entity3 . Its expression was moderate in normal pleura and limited in normal lung. @entity8 and @entity9 appear to be the best performing @entity2 markers in discriminating lung ACA from @entity5 compared with BerEp4 and @entity7 . There is no differential expression of @entity11 between the 2 pathologies. However, the limited @entity11 expression in normal tissues and high expression in @entity1 make it an attractive candidate for @entity1 therapy.

title: @entity8 , 4, and 15 expression in solid tumors of lung adenocarcinoma versus XXXX .

answer: @entity6


abstract: OBJECTIVES: Coltect is a novel dietary supplement containing @entity7 , green tea and @entity13 . Previous reports have suggested that these agents can prevent @entity1 ( @entity1 ). The present study examined the chemopreventive effect of Coltect alone or combined with @entity5 ( @entity6 ) using the @entity9 ( @entity11 ) model in @entity2 . METHODS: The effect of Coltect was examined on HT-29 @entity1 cells by growth inhibition assay. Apoptosis was determined by @entity10 - @entity4 /PI staining. Male @entity2 were injected with DMH in vivo and treated with Coltect 150   mg/kg, @entity6 50   mg/kg or their combination, by oral gavage. @entity12 ( @entity12 ) were identified by @entity8 staining. RESULTS: HT-29 cells exhibited a dose-dependent response to Coltect. Part of the growth inhibition can be explained by the induction of mild-moderate apoptosis in @entity0 cells (28%) compared with the untreated cells (10%). In the in vivo model, the average number of @entity12 was divided into small (1-3 crypts) or large (>= 4 crypts). The Coltect compound reduced the number of small and large @entity12 similarly to @entity6 (40% reduction). This reduction was amplified by combining the two agents (70% reduction). CONCLUSION: Coltect inhibits the growth of @entity3 cells, induces apoptosis and inhibits @entity12 development. Furthermore, it augments the growth inhibitory effect of @entity6 in vivo. This may be clinically important since this safe dietary supplement-drug combination can be administered as a chemopreventive regimen for the treatment of @entity1 .

title: Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with @entity5 in @entity9 -induced XXXX in @entity2 .

answer: @entity3


abstract: OBJECTIVES: Coltect is a novel dietary supplement containing @entity7 , green tea and @entity13 . Previous reports have suggested that these agents can prevent @entity1 ( @entity1 ). The present study examined the chemopreventive effect of Coltect alone or combined with @entity5 ( @entity6 ) using the @entity9 ( @entity11 ) model in @entity2 . METHODS: The effect of Coltect was examined on HT-29 @entity1 cells by growth inhibition assay. Apoptosis was determined by @entity10 - @entity4 /PI staining. Male @entity2 were injected with DMH in vivo and treated with Coltect 150   mg/kg, @entity6 50   mg/kg or their combination, by oral gavage. @entity12 ( @entity12 ) were identified by @entity8 staining. RESULTS: HT-29 cells exhibited a dose-dependent response to Coltect. Part of the growth inhibition can be explained by the induction of mild-moderate apoptosis in @entity0 cells (28%) compared with the untreated cells (10%). In the in vivo model, the average number of @entity12 was divided into small (1-3 crypts) or large (>= 4 crypts). The Coltect compound reduced the number of small and large @entity12 similarly to @entity6 (40% reduction). This reduction was amplified by combining the two agents (70% reduction). CONCLUSION: Coltect inhibits the growth of @entity3 cells, induces apoptosis and inhibits @entity12 development. Furthermore, it augments the growth inhibitory effect of @entity6 in vivo. This may be clinically important since this safe dietary supplement-drug combination can be administered as a chemopreventive regimen for the treatment of @entity1 .

title: Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with @entity5 in XXXX -induced @entity3 in @entity2 .

answer: @entity9


abstract: OBJECTIVES: Coltect is a novel dietary supplement containing @entity7 , green tea and @entity13 . Previous reports have suggested that these agents can prevent @entity1 ( @entity1 ). The present study examined the chemopreventive effect of Coltect alone or combined with @entity5 ( @entity6 ) using the @entity9 ( @entity11 ) model in @entity2 . METHODS: The effect of Coltect was examined on HT-29 @entity1 cells by growth inhibition assay. Apoptosis was determined by @entity10 - @entity4 /PI staining. Male @entity2 were injected with DMH in vivo and treated with Coltect 150   mg/kg, @entity6 50   mg/kg or their combination, by oral gavage. @entity12 ( @entity12 ) were identified by @entity8 staining. RESULTS: HT-29 cells exhibited a dose-dependent response to Coltect. Part of the growth inhibition can be explained by the induction of mild-moderate apoptosis in @entity0 cells (28%) compared with the untreated cells (10%). In the in vivo model, the average number of @entity12 was divided into small (1-3 crypts) or large (>= 4 crypts). The Coltect compound reduced the number of small and large @entity12 similarly to @entity6 (40% reduction). This reduction was amplified by combining the two agents (70% reduction). CONCLUSION: Coltect inhibits the growth of @entity3 cells, induces apoptosis and inhibits @entity12 development. Furthermore, it augments the growth inhibitory effect of @entity6 in vivo. This may be clinically important since this safe dietary supplement-drug combination can be administered as a chemopreventive regimen for the treatment of @entity1 .

title: Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with XXXX in @entity9 -induced @entity3 in @entity2 .

answer: @entity5


abstract: OBJECTIVES: Coltect is a novel dietary supplement containing @entity7 , green tea and @entity13 . Previous reports have suggested that these agents can prevent @entity1 ( @entity1 ). The present study examined the chemopreventive effect of Coltect alone or combined with @entity5 ( @entity6 ) using the @entity9 ( @entity11 ) model in @entity2 . METHODS: The effect of Coltect was examined on HT-29 @entity1 cells by growth inhibition assay. Apoptosis was determined by @entity10 - @entity4 /PI staining. Male @entity2 were injected with DMH in vivo and treated with Coltect 150   mg/kg, @entity6 50   mg/kg or their combination, by oral gavage. @entity12 ( @entity12 ) were identified by @entity8 staining. RESULTS: HT-29 cells exhibited a dose-dependent response to Coltect. Part of the growth inhibition can be explained by the induction of mild-moderate apoptosis in @entity0 cells (28%) compared with the untreated cells (10%). In the in vivo model, the average number of @entity12 was divided into small (1-3 crypts) or large (>= 4 crypts). The Coltect compound reduced the number of small and large @entity12 similarly to @entity6 (40% reduction). This reduction was amplified by combining the two agents (70% reduction). CONCLUSION: Coltect inhibits the growth of @entity3 cells, induces apoptosis and inhibits @entity12 development. Furthermore, it augments the growth inhibitory effect of @entity6 in vivo. This may be clinically important since this safe dietary supplement-drug combination can be administered as a chemopreventive regimen for the treatment of @entity1 .

title: Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with @entity5 in @entity9 -induced @entity3 in XXXX .

answer: @entity2


abstract: BACKGROUND: @entity2 ( @entity4 ) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. OBJECTIVE: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral @entity4 in @entity1 ( @entity1 ). METHODS: Twenty-four treatment-na  ve R-RMS @entity0 participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every @entity0 injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1   :   1) to either active oral @entity4 or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. RESULTS: In this small pilot investigation, no differences were identified between the two treatment groups with respect to @entity0 -reported adverse events, MRI metrics, or @entity3 . Notwithstanding these observations, and the limited number of @entity0 treated, trends appeared to favor the combination therapy regimen. CONCLUSIONS: The combination treatment regimen of interferon beta-1a and @entity4 appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of @entity4 in @entity1 appears warranted.

title: A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and @entity2 in early relapsing-remitting @entity1 (TIME XXXX ).

answer: @entity1


abstract: BACKGROUND: @entity2 ( @entity4 ) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. OBJECTIVE: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral @entity4 in @entity1 ( @entity1 ). METHODS: Twenty-four treatment-na  ve R-RMS @entity0 participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every @entity0 injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1   :   1) to either active oral @entity4 or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. RESULTS: In this small pilot investigation, no differences were identified between the two treatment groups with respect to @entity0 -reported adverse events, MRI metrics, or @entity3 . Notwithstanding these observations, and the limited number of @entity0 treated, trends appeared to favor the combination therapy regimen. CONCLUSIONS: The combination treatment regimen of interferon beta-1a and @entity4 appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of @entity4 in @entity1 appears warranted.

title: A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and @entity2 in early relapsing-remitting XXXX (TIME @entity1 ).

answer: @entity1


abstract: BACKGROUND: @entity2 ( @entity4 ) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. OBJECTIVE: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral @entity4 in @entity1 ( @entity1 ). METHODS: Twenty-four treatment-na  ve R-RMS @entity0 participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every @entity0 injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1   :   1) to either active oral @entity4 or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. RESULTS: In this small pilot investigation, no differences were identified between the two treatment groups with respect to @entity0 -reported adverse events, MRI metrics, or @entity3 . Notwithstanding these observations, and the limited number of @entity0 treated, trends appeared to favor the combination therapy regimen. CONCLUSIONS: The combination treatment regimen of interferon beta-1a and @entity4 appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of @entity4 in @entity1 appears warranted.

title: A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and XXXX in early relapsing-remitting @entity1 (TIME @entity1 ).

answer: @entity2


abstract: UNASSIGNED: @entity2 is a heterogeneous group of protein misfolding diseases characterized by deposition of amyloid proteins. The kidney is frequently affected, especially by immunoglobulin light chain ( @entity0 ) and @entity5 ( @entity5 ) @entity2 as the most common subgroups. Current diagnosis relies on histopathological examination, Congo red staining, or electron microscopy. Subtyping is done by immunohistochemistry; however, commercially available antibodies lack specificity. The purpose of this study was to identify and map amyloid proteins in formalin-fixed paraffin-embedded tissue sections using matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis in an integrated workflow. @entity6 and @entity2 biopsies were processed for histological and MS analysis. Mass spectra corresponding to the congophilic areas were directly linked to the histological and MS images for correlation studies. Peptides for @entity5 and @entity0 were detected by MALDI IMS associated to Congo red-positive areas. Sequence determination of amyloid peptides by LC-MS/MS analysis provided protein distribution and identification. Serum amyloid P component, @entity1 , and @entity3 proteins were identified in both @entity4 and @entity0 , showing a strong correlation with Congo red-positive regions. Our findings highlight the utility of MALDI IMS as a new method to type @entity2 in histopathological routine material and characterize amyloid-associated proteins that may provide insights into the pathogenetic process of amyloid formation.

title: Imaging mass spectrometry analysis of XXXX biopsies reveals protein co-localization with amyloid deposits.

answer: @entity6


abstract: PURPOSE: to examine the association between cytogenetic characteristics and clinical and epidemiological changes in @entity0 with @entity8 ( @entity8 ). METHODS: Forty-two @entity0 were included. Data were collected using a standardized questionnaire in interviews conducted with the responsible @entity0 and, when possible, with the @entity0 . A detailed physical examination was performed. The association between karyotype, stigmata and clinical disorders were examined using the   2 test. RESULTS: Sixty-four percent of @entity8 @entity0 were 45,X; 26,2% 45,X/46,X;7% 45,X/46Xi(Xq), and 2,3% 45,X/46,X,Del(Xq). Regardless of the karyotype, all @entity0 had @entity4 . Low hair implantation was more frequent in @entity0 with 45,X (p=0.03). @entity1 (45%), @entity7 (43%), @entity5 (33%) and @entity2 (26.6%) were the most frequent clinical disorders, but without correlation with the karyotype. Anthropometric measurements revealed a positive linear correlation of waist and hip circumference with age (r=0.9, p=0.01). Thirty-one @entity0 (74%) were using or had previously used growth hormone (43%), sex @entity3 (30%), @entity6 (11.9%) or @entity9 (9.5%). Comparison between gestational age at birth and learning difficulties showed a prevalence ratio of 1.71 (p>0.05). CONCLUSION: Low hair implantation is the most prevalent stigma in @entity0 with a 45,X karyotype and the most common clinical changes were cardiovascular problems, @entity7 , @entity5 and @entity2 ; however, they did not show any correlation with the karyotype.

title: [Clinical and cytogenetic aspects of the XXXX in the Brazilian Western region].

answer: @entity8


abstract: BACKGROUND: Myocardial @entity4 is altered in left @entity1 . In @entity0 with @entity2 ( @entity2 ), this issue has not been addressed. OBJECTIVE: To determine the level of myocardial @entity4 in @entity0 with @entity2 and compare it in @entity0 with @entity3 , and to relate myocardial @entity4 to left ventricular ejection fraction (LVEF). METHODS: We studied 39 @entity0 with @entity2 , divided into group 1: 21 individuals with normal LVEF and group 2: 18 individuals with decreased LVEF. Seventeen @entity0 with @entity3 were divided into group 3: 12 individuals with normal LVEF and group 4: 5 individuals with decreased LVEF. Two-dimensional echocardiography was used to measure LVEF. Myocardial @entity4 was determined by high-performance liquid chromatography. RESULTS: Myocardial @entity4 in @entity2 with and without @entity1 was 1.3  1.3 and 6.1  4.2 pg/ g noncollagen protein, respectively (p<0.0001); in @entity3 with and without @entity1 , it was 3.3  3.0 and 9.8  4.2 pg/ g noncollagen protein, respectively (p<0.0001). A positive correlation was found between LVEF and myocardial @entity4 concentration in the @entity0 with @entity2 (p<0.01, r = 0.57) and also in those with @entity3 (p<0.01, r=0.69). A significant difference was demonstrated between @entity4 concentrations in @entity0 with normal LVEF (groups 1 and 3; p = 0.0182), but no difference was found in @entity0 with decreased LVEF (groups 2 and 4; p = 0.1467). CONCLUSION: In @entity0 with @entity2 and normal global ejection fraction there is an early cardiac denervation, when compared to @entity3 @entity0 .

title: Intramyocardial adrenergic activation in chagasic XXXX and @entity3 .

answer: @entity2


abstract: BACKGROUND: Myocardial @entity4 is altered in left @entity1 . In @entity0 with @entity2 ( @entity2 ), this issue has not been addressed. OBJECTIVE: To determine the level of myocardial @entity4 in @entity0 with @entity2 and compare it in @entity0 with @entity3 , and to relate myocardial @entity4 to left ventricular ejection fraction (LVEF). METHODS: We studied 39 @entity0 with @entity2 , divided into group 1: 21 individuals with normal LVEF and group 2: 18 individuals with decreased LVEF. Seventeen @entity0 with @entity3 were divided into group 3: 12 individuals with normal LVEF and group 4: 5 individuals with decreased LVEF. Two-dimensional echocardiography was used to measure LVEF. Myocardial @entity4 was determined by high-performance liquid chromatography. RESULTS: Myocardial @entity4 in @entity2 with and without @entity1 was 1.3  1.3 and 6.1  4.2 pg/ g noncollagen protein, respectively (p<0.0001); in @entity3 with and without @entity1 , it was 3.3  3.0 and 9.8  4.2 pg/ g noncollagen protein, respectively (p<0.0001). A positive correlation was found between LVEF and myocardial @entity4 concentration in the @entity0 with @entity2 (p<0.01, r = 0.57) and also in those with @entity3 (p<0.01, r=0.69). A significant difference was demonstrated between @entity4 concentrations in @entity0 with normal LVEF (groups 1 and 3; p = 0.0182), but no difference was found in @entity0 with decreased LVEF (groups 2 and 4; p = 0.1467). CONCLUSION: In @entity0 with @entity2 and normal global ejection fraction there is an early cardiac denervation, when compared to @entity3 @entity0 .

title: Intramyocardial adrenergic activation in chagasic @entity2 and XXXX .

answer: @entity3


abstract: INTRODUCTION: Report the incidence of @entity3 , causative microorganisms, risk factors associated with and antimicrobial susceptibility pattern in the NICU of the Uberl  ndia University Hospital. METHODS: Data were collected through the National Healthcare Safety Network surveillance from January 2006 to December 2009. The @entity0 were followed five times/week from their birth to their discharge or @entity1 . RESULTS: The study included 1,443 @entity0 , 209 of these developed NIs, totaling 293 NI episodes, principally bloodstream infections (203; 69.3%) and @entity5 (52; 17.7%). Device-associated @entity2 rates were as follows: 17.3 primary bloodstream infections per 1,000 central line-days and 3.2 pneumonias per 1000 ventilator-days. The mortality rate in neonates with NI was 11.9%. Mechanical ventilation, total parenteral nutrition, orogastric tube, previous antibiotic therapy, use of CVC and birth weight of 751-1,000g appeared to be associated with a significantly higher risk of NI (p < 0.05). In multiple logistic regression analysis for NI, mechanical ventilation and the use of CVC were independent risk factors (p < 0.05). Coagulase- negative @entity4 (CoNS) (36.5%) and @entity4 (23.6%) were the most common etiologic agents isolated from cultures. The incidences of @entity6 -resistant CoNS and @entity4 were 81.8% and 25.3%, respectively. CONCLUSIONS: Frequent surveillance was very important to evaluate the association of these well-known risk factors with NIs and causative organisms, assisting in drawing the attention of health care professionals to this potent cause of morbidity.

title: XXXX in a Brazilian neonatal intensive care unit: a 4-year surveillance study.

answer: @entity3


abstract: Rupture of a hydatid cyst into the biliary tract, also known as cystobiliary communication, is the most common complication of hepatic hydatid cyst. This may lead to obstructive @entity5 , @entity4 , @entity1 , and @entity2 with high mortality. Imaging plays an important role in the preoperative diagnosis of this condition which facilitates its management. We studied six @entity0 with @entity3 of hepatic hydatid cyst into a large bile duct in whom multidetector-row CT (MDCT) suggested the diagnosis. The imaging findings included a single hepatic cyst less than 10 cm in diameter in all the cases; interruption of the cyst wall adjacent to a bile duct signifying cyst-bile duct communication was seen in five @entity0 . The common bile duct was dilated in all the @entity0 , with linear membranes in four and diffuse irregular high dense intrabiliary material observed within the common bile duct in two of them. Intrahepatic ducts were dilated in all the six cases and two @entity0 showed linear dense contents within distended gallbladder. Subcapsular and intrathoracic @entity3 was associated in one @entity0 each. MDCT demonstration of hydatid cyst in the liver together with a dilated common bile duct and distended gallbladder containing high density hydatid material suggest @entity3 of the cyst into biliary tree. MDCT enhances demonstration of the dilated common bile duct with hydatid material inside. The diagnosis is reinforced by the demonstration of the cystobiliary communication itself.

title: XXXX of hepatic hydatid cyst: multidetector-row CT demonstration.

answer: @entity3


abstract: BACKGROUND: @entity4 ( @entity4 ) resolves rapidly after bariatric surgery, even before substantial weight is lost. However, the molecular pathways underlying this phenomenon remain unclear. Microarray data has shown that numerous genes are differentially expressed in blood after bariatric surgery, including @entity5 and @entity3 . @entity5 and @entity3 are circulating hormones derived from adipose tissue, which are associated with @entity2 and insulin resistance. This study examined expression of these genes before and after bariatric surgery in @entity1 @entity0 . METHODS: The study included 16 @entity2 @entity0 who underwent bariatric surgery, either Roux-en-Y gastric bypass (RYGB) or adjustable gastric banding. Eight @entity0 had @entity4 . Preoperative blood samples were collected in PAXgene tubes to stabilize mRNA. Postoperative samples were collected 3 months after surgery. Total RNA was isolated and cDNA was synthesized. Real-time quantitative PCR was used to quantify mRNA. Results were analyzed using Student's t test with a P<0.05 considered significant. RESULTS: Postoperatively, five @entity1 @entity0 had discontinued hypoglycemic medications and one showed improved glycemic control. Both @entity3 and @entity5 mRNA levels were elevated in the @entity1 group but decreased after surgery to levels near those of the nondiabetic group. Greater downregulation of @entity5 and @entity3 expression occurred in @entity0 who lost more excess body weight (EBW), while @entity0 who lost less than 10% EBW had a mean increase in expression of the two genes. Downregulation of both genes was more pronounced after RYGB compared to gastric banding. CONCLUSIONS: Downregulation of @entity5 and @entity3 gene expression after bariatric surgery may play a role in normalizing @entity2 -associated insulin resistance. Interestingly, downregulation is greater after RYGB and in @entity0 who lose a greater proportion of EBW. Targeted therapies for @entity2 and @entity1 may be developed by understanding the pathways by which these adipocytokines contribute to @entity2 and @entity4 .

title: Downregulation of @entity3 and XXXX expression in blood following bariatric surgery.

answer: @entity5


abstract: BACKGROUND: @entity4 ( @entity4 ) resolves rapidly after bariatric surgery, even before substantial weight is lost. However, the molecular pathways underlying this phenomenon remain unclear. Microarray data has shown that numerous genes are differentially expressed in blood after bariatric surgery, including @entity5 and @entity3 . @entity5 and @entity3 are circulating hormones derived from adipose tissue, which are associated with @entity2 and insulin resistance. This study examined expression of these genes before and after bariatric surgery in @entity1 @entity0 . METHODS: The study included 16 @entity2 @entity0 who underwent bariatric surgery, either Roux-en-Y gastric bypass (RYGB) or adjustable gastric banding. Eight @entity0 had @entity4 . Preoperative blood samples were collected in PAXgene tubes to stabilize mRNA. Postoperative samples were collected 3 months after surgery. Total RNA was isolated and cDNA was synthesized. Real-time quantitative PCR was used to quantify mRNA. Results were analyzed using Student's t test with a P<0.05 considered significant. RESULTS: Postoperatively, five @entity1 @entity0 had discontinued hypoglycemic medications and one showed improved glycemic control. Both @entity3 and @entity5 mRNA levels were elevated in the @entity1 group but decreased after surgery to levels near those of the nondiabetic group. Greater downregulation of @entity5 and @entity3 expression occurred in @entity0 who lost more excess body weight (EBW), while @entity0 who lost less than 10% EBW had a mean increase in expression of the two genes. Downregulation of both genes was more pronounced after RYGB compared to gastric banding. CONCLUSIONS: Downregulation of @entity5 and @entity3 gene expression after bariatric surgery may play a role in normalizing @entity2 -associated insulin resistance. Interestingly, downregulation is greater after RYGB and in @entity0 who lose a greater proportion of EBW. Targeted therapies for @entity2 and @entity1 may be developed by understanding the pathways by which these adipocytokines contribute to @entity2 and @entity4 .

title: Downregulation of XXXX and @entity5 expression in blood following bariatric surgery.

answer: @entity3


abstract: UNASSIGNED: The psychopathological symptoms occurring in the course of diseases associated with @entity5 are often initially isolated and non-characteristic, and may cause diagnostic difficulties. Moreover, such disorders tend to be less responsive to @entity3 management. Among possible causes such as @entity2 , @entity1 and vascular changes, inflammatory changes of the brain as a  result of a  @entity6 should also be considered. There were 452 registered cases of @entity10 in Poland in 2010, and although not very prevalent they remain a  severe and life-threatening condition. What is more, the frequently occurring neurological and @entity3 complications of @entity10 often result in @entity7 , causing a  significant decrease in the quality of life. This article presents the three types of @entity4 that are most prevalent among immunocompetent @entity0 in Poland, i.e. @entity9 ( @entity9 ), @entity11 ( @entity11 ) and herpes @entity8 (HZE). The psychopathology of the acute phase of the @entity5 , the residual symptoms, features apparent in imaging studies and some neuropathological aspects are also presented. The paper also focuses on @entity3 aspects of the diagnostics and treatment of the described conditions. The clinical pictures of these @entity5 are quite specific, although they cover a  wide range of symptoms, and these characteristic features are described. The aim of this review is also to show the significance of thorough diagnostics and a  multidisciplinary approach to @entity0 with @entity12 .

title: Psychiatric Aspects of Herpes Simplex @entity4 , XXXX and Herpes @entity8 Among Immunocompetent @entity0 .

answer: @entity11


abstract: UNASSIGNED: The psychopathological symptoms occurring in the course of diseases associated with @entity5 are often initially isolated and non-characteristic, and may cause diagnostic difficulties. Moreover, such disorders tend to be less responsive to @entity3 management. Among possible causes such as @entity2 , @entity1 and vascular changes, inflammatory changes of the brain as a  result of a  @entity6 should also be considered. There were 452 registered cases of @entity10 in Poland in 2010, and although not very prevalent they remain a  severe and life-threatening condition. What is more, the frequently occurring neurological and @entity3 complications of @entity10 often result in @entity7 , causing a  significant decrease in the quality of life. This article presents the three types of @entity4 that are most prevalent among immunocompetent @entity0 in Poland, i.e. @entity9 ( @entity9 ), @entity11 ( @entity11 ) and herpes @entity8 (HZE). The psychopathology of the acute phase of the @entity5 , the residual symptoms, features apparent in imaging studies and some neuropathological aspects are also presented. The paper also focuses on @entity3 aspects of the diagnostics and treatment of the described conditions. The clinical pictures of these @entity5 are quite specific, although they cover a  wide range of symptoms, and these characteristic features are described. The aim of this review is also to show the significance of thorough diagnostics and a  multidisciplinary approach to @entity0 with @entity12 .

title: Psychiatric Aspects of Herpes Simplex XXXX , @entity11 and Herpes @entity8 Among Immunocompetent @entity0 .

answer: @entity4


abstract: UNASSIGNED: The psychopathological symptoms occurring in the course of diseases associated with @entity5 are often initially isolated and non-characteristic, and may cause diagnostic difficulties. Moreover, such disorders tend to be less responsive to @entity3 management. Among possible causes such as @entity2 , @entity1 and vascular changes, inflammatory changes of the brain as a  result of a  @entity6 should also be considered. There were 452 registered cases of @entity10 in Poland in 2010, and although not very prevalent they remain a  severe and life-threatening condition. What is more, the frequently occurring neurological and @entity3 complications of @entity10 often result in @entity7 , causing a  significant decrease in the quality of life. This article presents the three types of @entity4 that are most prevalent among immunocompetent @entity0 in Poland, i.e. @entity9 ( @entity9 ), @entity11 ( @entity11 ) and herpes @entity8 (HZE). The psychopathology of the acute phase of the @entity5 , the residual symptoms, features apparent in imaging studies and some neuropathological aspects are also presented. The paper also focuses on @entity3 aspects of the diagnostics and treatment of the described conditions. The clinical pictures of these @entity5 are quite specific, although they cover a  wide range of symptoms, and these characteristic features are described. The aim of this review is also to show the significance of thorough diagnostics and a  multidisciplinary approach to @entity0 with @entity12 .

title: Psychiatric Aspects of Herpes Simplex @entity4 , @entity11 and Herpes XXXX Among Immunocompetent @entity0 .

answer: @entity8


abstract: UNASSIGNED: The psychopathological symptoms occurring in the course of diseases associated with @entity5 are often initially isolated and non-characteristic, and may cause diagnostic difficulties. Moreover, such disorders tend to be less responsive to @entity3 management. Among possible causes such as @entity2 , @entity1 and vascular changes, inflammatory changes of the brain as a  result of a  @entity6 should also be considered. There were 452 registered cases of @entity10 in Poland in 2010, and although not very prevalent they remain a  severe and life-threatening condition. What is more, the frequently occurring neurological and @entity3 complications of @entity10 often result in @entity7 , causing a  significant decrease in the quality of life. This article presents the three types of @entity4 that are most prevalent among immunocompetent @entity0 in Poland, i.e. @entity9 ( @entity9 ), @entity11 ( @entity11 ) and herpes @entity8 (HZE). The psychopathology of the acute phase of the @entity5 , the residual symptoms, features apparent in imaging studies and some neuropathological aspects are also presented. The paper also focuses on @entity3 aspects of the diagnostics and treatment of the described conditions. The clinical pictures of these @entity5 are quite specific, although they cover a  wide range of symptoms, and these characteristic features are described. The aim of this review is also to show the significance of thorough diagnostics and a  multidisciplinary approach to @entity0 with @entity12 .

title: Psychiatric Aspects of Herpes Simplex @entity4 , @entity11 and Herpes @entity8 Among Immunocompetent XXXX .

answer: @entity0


abstract: BACKGROUND AND PURPOSE: Multiple methods to detect @entity4 ( @entity4 ) in @entity0 with @entity2 are available. However, it is unknown which approaches are currently used in clinical routine and guidelines remain vague to the extent of cardiac monitoring. We characterize diagnostic efforts for @entity4 detection on German @entity2 units (SU). METHODS: A standardized anonymous questionnaire was sent to all clinical leads of certified SUs in Germany. The questionnaire focused on basic characteristics of SUs, procedures to detect AF, and estimates on AF detection. RESULTS: One hundred seventy-nine SU leads participated (response rate 71.6%). All @entity0 undergo continuous bedside ECG monitoring. A percentage of 77.6 SUs initiate additional 24-hour Holter ECG in >50% of @entity0 without known AF. @entity0 with transient @entity1 attack are monitored significantly shorter than @entity0 with @entity3 . Independent of SU type or size, 67.6% of leads assumed to fail detecting @entity4 in 5% to 20% of @entity0 . In cryptogenic @entity2 , additional ECG monitoring is recommended by 90.2% but only 13.8% of SUs perform routine ECG follow-up visits. The use of implanted event recorders is low (1-10 @entity0 /y by 60.7% of SUs; 28.1%: no use). A percentage of 83.9 do not use external event recorders. CONCLUSIONS: Our survey demonstrates substantial heterogeneity among German SUs on diagnostic work-up for @entity4 . Future prospective multicenter studies should systematically evaluate the impact of different methods to uncover @entity4 .

title: Diagnostic work-up for detection of @entity4 after acute @entity3 : cross-sectional survey on german XXXX units.

answer: @entity2


abstract: BACKGROUND AND PURPOSE: Multiple methods to detect @entity4 ( @entity4 ) in @entity0 with @entity2 are available. However, it is unknown which approaches are currently used in clinical routine and guidelines remain vague to the extent of cardiac monitoring. We characterize diagnostic efforts for @entity4 detection on German @entity2 units (SU). METHODS: A standardized anonymous questionnaire was sent to all clinical leads of certified SUs in Germany. The questionnaire focused on basic characteristics of SUs, procedures to detect AF, and estimates on AF detection. RESULTS: One hundred seventy-nine SU leads participated (response rate 71.6%). All @entity0 undergo continuous bedside ECG monitoring. A percentage of 77.6 SUs initiate additional 24-hour Holter ECG in >50% of @entity0 without known AF. @entity0 with transient @entity1 attack are monitored significantly shorter than @entity0 with @entity3 . Independent of SU type or size, 67.6% of leads assumed to fail detecting @entity4 in 5% to 20% of @entity0 . In cryptogenic @entity2 , additional ECG monitoring is recommended by 90.2% but only 13.8% of SUs perform routine ECG follow-up visits. The use of implanted event recorders is low (1-10 @entity0 /y by 60.7% of SUs; 28.1%: no use). A percentage of 83.9 do not use external event recorders. CONCLUSIONS: Our survey demonstrates substantial heterogeneity among German SUs on diagnostic work-up for @entity4 . Future prospective multicenter studies should systematically evaluate the impact of different methods to uncover @entity4 .

title: Diagnostic work-up for detection of XXXX after acute @entity3 : cross-sectional survey on german @entity2 units.

answer: @entity4


abstract: BACKGROUND AND PURPOSE: Multiple methods to detect @entity4 ( @entity4 ) in @entity0 with @entity2 are available. However, it is unknown which approaches are currently used in clinical routine and guidelines remain vague to the extent of cardiac monitoring. We characterize diagnostic efforts for @entity4 detection on German @entity2 units (SU). METHODS: A standardized anonymous questionnaire was sent to all clinical leads of certified SUs in Germany. The questionnaire focused on basic characteristics of SUs, procedures to detect AF, and estimates on AF detection. RESULTS: One hundred seventy-nine SU leads participated (response rate 71.6%). All @entity0 undergo continuous bedside ECG monitoring. A percentage of 77.6 SUs initiate additional 24-hour Holter ECG in >50% of @entity0 without known AF. @entity0 with transient @entity1 attack are monitored significantly shorter than @entity0 with @entity3 . Independent of SU type or size, 67.6% of leads assumed to fail detecting @entity4 in 5% to 20% of @entity0 . In cryptogenic @entity2 , additional ECG monitoring is recommended by 90.2% but only 13.8% of SUs perform routine ECG follow-up visits. The use of implanted event recorders is low (1-10 @entity0 /y by 60.7% of SUs; 28.1%: no use). A percentage of 83.9 do not use external event recorders. CONCLUSIONS: Our survey demonstrates substantial heterogeneity among German SUs on diagnostic work-up for @entity4 . Future prospective multicenter studies should systematically evaluate the impact of different methods to uncover @entity4 .

title: Diagnostic work-up for detection of @entity4 after acute XXXX : cross-sectional survey on german @entity2 units.

answer: @entity3


abstract: OBJECTIVES: To explore interactions between audiology @entity0 and volunteers, to describe encounters and define the role of volunteers. METHODS: Qualitative ethnographic and interview study of volunteer- @entity0 interactions. Ten volunteer @entity0 from two volunteer schemes in South West England were observed and interviewed. Three @entity0 @entity0 were interviewed. RESULTS: Analysis of observational data showed that volunteers provided support relating to local services and hearing aids, but did not engage in discussions about @entity1 . Interviews with volunteers identified gaps in audiology provision, including accessible services and clear information and highlighted a need for more support from audiology services to enable them to fulfil their role. @entity2 with @entity0 mimicked a clinician- @entity0 encounter and volunteers employed strategies and behaviours used by professional audiologists. CONCLUSIONS: Audiology volunteers could provide an accessible bridge between health services and the community but their care is limited to focus on hearing aids. PRACTICE IMPLICATIONS: Volunteers enable @entity0 to use hearing aids appropriately and are a core element of current care arrangements. However, volunteers express a need for adequate support from audiology services. Volunteers have the potential to increase service capacity and to bridge the gaps between community and audiology healthcare services.

title: The role of volunteer support in the community for adults with XXXX and hearing aids.

answer: @entity1


abstract: Cell-based therapy has achieved promising functional recovery for peripheral nerve repair. Although Schwann cells (SCs) and bone marrow derived mesenchymal stromal cells (BM-MSCs) are the main cell source for nerve tissue engineering, the clinical application is limited because of donor site morbidity, the invasive procedure, and the decreased number of SCs and BM-MSCs. Wharton's jelly-derived mesenchymal stem cells (WJMSCs) could be a promising cell source for nerve tissue engineering because they are easily accessible and their use has no ethical issues. We investigated the phenotypic, molecular and functional characteristics of WJMSCs differentiated along a Schwann-cell lineage. Cultured WJMSCs were isolated from @entity0 umbilical cord, and the undifferentiated WJMSCs were confirmed by the detection of MSC-specific cell-surface markers. WJMSCs treated with a mixture of glial growth factors (basic fibroblast growth factor, platelet-derived growth factor and @entity1 ) adopted a spindle-like morphology similar to SCs. Immunocytochemical staining, RT-PCR analysis, and Western blot analysis revealed that the treated cells expressed the glial markers glial fibrillary acidic protein, @entity2 , S100 and P0 and indicative of differentiation. On co-culture with dorsal root ganglia neurons, the differentiated WJMSCs enhanced the number of sprouting neurites and neurite length in dorsal root ganglia neurons. Furthermore, using enzyme-linked immunosorbent assay and RT-PCR methodology, we found differentiated WJMSCs secrete and express neurotrophic factors, including @entity3 ( @entity3 ), @entity4 ( @entity4 ), and @entity5 (NT-3). Quantification of neurite outgrowth from PC12 cells grown in differentiated WJMSCs-conditioned media demonstrates that the neurite length is significantly more than control medium and undifferentiated WJMSCs group. WJMSCs can be differentiated into cells that are Schwann-like in terms of morphologic features, phenotype, and function and could be suitable Schwann-cell substitutes for nerve repair in clinical applications.

title: XXXX umbilical cord Wharton's jelly-derived mesenchymal stem cells differentiate into a Schwann-cell phenotype and promote neurite outgrowth in vitro.

answer: @entity0


abstract: OBJECTIVE: Coverage of celiac artery (CA) during @entity6 repair (TEVAR) has been performed to extend the distal seal zone for which preliminary results and short-term follow-up have been reported. We aim to show the outcomes up to 81  months after CA coverage during TEVAR. METHODS: @entity0 undergoing TEVAR with coverage of the CA origin from 2005 to 2013 were retrospectively analyzed. Points of analysis include indications for covering the CA, demonstration of collateral circulation between the CA and @entity8 ( @entity8 ), anatomic features of the distal landing zone, rate of reintervention, technical success, presence of clinical @entity1 symptoms after the procedure, and mortality. RESULTS: During the 9-year period, 366 @entity0 underwent TEVAR, 18 (5%) of whom had CA coverage. Eleven (61%) had TEVAR with CA coverage due to a @entity5 , three (17%) had thoracic aortic dissection related to @entity5 , and four (22%) had previous TEVAR with a type Ib endoleak (EL) requiring distal coverage. Mesenteric angiography in preparation for TEVAR with CA coverage diagnosed a @entity8 in one @entity0 that was treated with stenting before the index procedure. At the conclusion of the indicated procedure, two @entity0 (11%) had a type Ia EL and two @entity0 (11%) had a type Ib EL. Three of the type I ELs required reintervention. Two @entity0 (11%) had a type II EL, both of which were managed with observation and resolved. Reintervention was required in 27% of @entity0 . @entity3 included @entity1 in 2 (11%), @entity4 in 1 (5%), @entity7 in 2 (11%), a cerebrovascular event in 1 (6%), and @entity2 in 1 (6%). The mean follow-up period was 38  months (range, 0.5-81  months). CONCLUSIONS: This analysis of outcomes up to 81  months supports the suitability of covering the CA in selected @entity0 for extending the distal landing zone to the visceral aortic level above the @entity8 or when alternative branch vessel treatment is unavailable. Preoperative angiographic evaluation of the mesenteric collaterals and early postoperative surveillance may limit @entity3 . Once the CA is covered, new symptoms do not develop unless the @entity8 is compromised.

title: Outcomes up to 81  months after celiac artery coverage during XXXX repair.

answer: @entity6


abstract: OBJECTIVE: To study whether physician presence in the nursing home is related to clinical decision making, certainty, and honoring care preferences for @entity0 with @entity2 and @entity1 . DESIGN: Cross-sectional survey of physicians. SETTING: Nursing homes in the United States and the Netherlands. @entity0 : Twenty-four US and 38 Dutch physicians who provide care for nursing home @entity0 . MEASUREMENTS: Physicians reported their presence in the nursing home, diagnostic and treatment decisions for @entity0 with @entity2 who had @entity1 , certainty about the diagnosis and @entity0 and family preferences, and the extent to which they honored these preferences. These variables were examined in reference to physician presence in the nursing home. RESULTS: Physicians with higher nursing home presence were less likely to order a chest x-ray and to hospitalize @entity0 with @entity2 and @entity1 , although this difference was not significant when adjusted for country. They also were more likely to be certain of family preferences, a difference that held even when adjusted for the strong confounder of country. CONCLUSION: Physician presence in the nursing home relates to some treatment decisions for @entity0 with @entity2 and @entity1 . Policies that affect physician presence may change health care practices and related costs. Future studies should more closely examine how physicians use their time so as to better understand the importance of presence and what the US health care system might learn from the Dutch system.

title: The importance of physician presence in nursing homes for residents with @entity2 and XXXX .

answer: @entity1


abstract: OBJECTIVE: To study whether physician presence in the nursing home is related to clinical decision making, certainty, and honoring care preferences for @entity0 with @entity2 and @entity1 . DESIGN: Cross-sectional survey of physicians. SETTING: Nursing homes in the United States and the Netherlands. @entity0 : Twenty-four US and 38 Dutch physicians who provide care for nursing home @entity0 . MEASUREMENTS: Physicians reported their presence in the nursing home, diagnostic and treatment decisions for @entity0 with @entity2 who had @entity1 , certainty about the diagnosis and @entity0 and family preferences, and the extent to which they honored these preferences. These variables were examined in reference to physician presence in the nursing home. RESULTS: Physicians with higher nursing home presence were less likely to order a chest x-ray and to hospitalize @entity0 with @entity2 and @entity1 , although this difference was not significant when adjusted for country. They also were more likely to be certain of family preferences, a difference that held even when adjusted for the strong confounder of country. CONCLUSION: Physician presence in the nursing home relates to some treatment decisions for @entity0 with @entity2 and @entity1 . Policies that affect physician presence may change health care practices and related costs. Future studies should more closely examine how physicians use their time so as to better understand the importance of presence and what the US health care system might learn from the Dutch system.

title: The importance of physician presence in nursing homes for residents with XXXX and @entity1 .

answer: @entity2


abstract: AIMS: To conduct a @entity0 -level meta-analysis of the EDITION 1, 2 and 3 studies, which compared the efficacy and safety of new insulin glargine 300 U/ml ( @entity4 -300) with insulin glargine 100 U/ml ( @entity4 -100) in @entity0 with type 2 @entity1 (T2DM) on basal and mealtime insulin, basal insulin and oral antihyperglycaemic drugs, or no prior insulin, respectively. METHODS: The EDITION studies were multicentre, randomized, open-label, parallel-group, phase IIIa studies, with similar designs and endpoints. A @entity0 -level meta-analysis of the studies enabled these endpoints to be examined over 6 months in a large population with T2DM ( @entity4 -300, n = 1247; @entity4 -100, n = 1249). RESULTS: No significant study-by-treatment interactions across studies were found, enabling them to be pooled. The mean change in glycated haemoglobin was comparable for @entity4 -300 and @entity4 -100 [each -1.02 (standard error 0.03)%; least squares (LS) mean difference 0.00 (95% confidence interval (CI) -0.08 to 0.07)%]. Annualized rates of confirmed ( <=3.9 mmol/l) or severe hypoglycaemia were lower with @entity4 -300 than with @entity4 -100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference). Consistent reductions were observed in percentage of @entity0 with >= 1 hypoglycaemic event. Severe hypoglycaemia at any time (24 h) was rare ( @entity4 -300: 2.3%; @entity4 -100: 2.6%). Weight gain was low (<1 kg) in both groups, with @entity2 with @entity4 -300 [LS mean difference -0.28 kg (95% CI -0.55 to -0.01); p = 0.039]. Both treatments were well tolerated, with similar rates of adverse events. CONCLUSION: @entity4 -300 provides comparable glycaemic control to @entity4 -100 in a large population with a broad clinical spectrum of T2DM, with consistently less hypoglycaemia at any time of day and @entity3 .

title: @entity0 -level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in @entity0 with type 2 XXXX .

answer: @entity1


abstract: AIMS: To conduct a @entity0 -level meta-analysis of the EDITION 1, 2 and 3 studies, which compared the efficacy and safety of new insulin glargine 300 U/ml ( @entity4 -300) with insulin glargine 100 U/ml ( @entity4 -100) in @entity0 with type 2 @entity1 (T2DM) on basal and mealtime insulin, basal insulin and oral antihyperglycaemic drugs, or no prior insulin, respectively. METHODS: The EDITION studies were multicentre, randomized, open-label, parallel-group, phase IIIa studies, with similar designs and endpoints. A @entity0 -level meta-analysis of the studies enabled these endpoints to be examined over 6 months in a large population with T2DM ( @entity4 -300, n = 1247; @entity4 -100, n = 1249). RESULTS: No significant study-by-treatment interactions across studies were found, enabling them to be pooled. The mean change in glycated haemoglobin was comparable for @entity4 -300 and @entity4 -100 [each -1.02 (standard error 0.03)%; least squares (LS) mean difference 0.00 (95% confidence interval (CI) -0.08 to 0.07)%]. Annualized rates of confirmed ( <=3.9 mmol/l) or severe hypoglycaemia were lower with @entity4 -300 than with @entity4 -100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference). Consistent reductions were observed in percentage of @entity0 with >= 1 hypoglycaemic event. Severe hypoglycaemia at any time (24 h) was rare ( @entity4 -300: 2.3%; @entity4 -100: 2.6%). Weight gain was low (<1 kg) in both groups, with @entity2 with @entity4 -300 [LS mean difference -0.28 kg (95% CI -0.55 to -0.01); p = 0.039]. Both treatments were well tolerated, with similar rates of adverse events. CONCLUSION: @entity4 -300 provides comparable glycaemic control to @entity4 -100 in a large population with a broad clinical spectrum of T2DM, with consistently less hypoglycaemia at any time of day and @entity3 .

title: XXXX -level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in @entity0 with type 2 @entity1 .

answer: @entity0


abstract: AIMS: To conduct a @entity0 -level meta-analysis of the EDITION 1, 2 and 3 studies, which compared the efficacy and safety of new insulin glargine 300 U/ml ( @entity4 -300) with insulin glargine 100 U/ml ( @entity4 -100) in @entity0 with type 2 @entity1 (T2DM) on basal and mealtime insulin, basal insulin and oral antihyperglycaemic drugs, or no prior insulin, respectively. METHODS: The EDITION studies were multicentre, randomized, open-label, parallel-group, phase IIIa studies, with similar designs and endpoints. A @entity0 -level meta-analysis of the studies enabled these endpoints to be examined over 6 months in a large population with T2DM ( @entity4 -300, n = 1247; @entity4 -100, n = 1249). RESULTS: No significant study-by-treatment interactions across studies were found, enabling them to be pooled. The mean change in glycated haemoglobin was comparable for @entity4 -300 and @entity4 -100 [each -1.02 (standard error 0.03)%; least squares (LS) mean difference 0.00 (95% confidence interval (CI) -0.08 to 0.07)%]. Annualized rates of confirmed ( <=3.9 mmol/l) or severe hypoglycaemia were lower with @entity4 -300 than with @entity4 -100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference). Consistent reductions were observed in percentage of @entity0 with >= 1 hypoglycaemic event. Severe hypoglycaemia at any time (24 h) was rare ( @entity4 -300: 2.3%; @entity4 -100: 2.6%). Weight gain was low (<1 kg) in both groups, with @entity2 with @entity4 -300 [LS mean difference -0.28 kg (95% CI -0.55 to -0.01); p = 0.039]. Both treatments were well tolerated, with similar rates of adverse events. CONCLUSION: @entity4 -300 provides comparable glycaemic control to @entity4 -100 in a large population with a broad clinical spectrum of T2DM, with consistently less hypoglycaemia at any time of day and @entity3 .

title: @entity0 -level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in XXXX with type 2 @entity1 .

answer: @entity0


abstract: @entity1 in pregnancy are a diagnostic and management challenge that is increasingly being faced by the clinician. While most masses are benign and resolve spontaneously, there are others that persist and indicate the need for surgical management. Ultrasound not only detects asymptomatic masses but also helps to guide their management based on presence or absence of features suspicious of @entity0 . The role of @entity0 markers in pregnancy is limited due to their non-specific nature. Most masses treated in pregnancy are benign (most commonly dermoids), and most @entity0 are either of low malignant potential or germ cell @entity0 , usually early stage disease. Surgical management is indicated for symptomatic masses or those with increasing size or complexity indicating possible @entity0 . Both laparoscopy and laparotomy have similar results with regard to obstetric outcome. Conservative management is preferred in the remainder. MRI may help in better characterization of doubtful masses. National @entity0 registries can help to establish guidelines.

title: XXXX in pregnancy: a literature review.

answer: @entity1


abstract: PURPOSE: Recent innovations in CT enable the evolution from mere morphologic imaging to dynamic and functional testing. We describe our initial experience performing myocardial stress perfusion CT in a clinical population with acute @entity2 . METHODS AND MATERIALS: Myocardial stress perfusion CT was performed on twenty consecutive @entity0 (15 @entity0 , 5 @entity0 ; mean age 65    8 years) who presented with acute @entity2 and were clinically referred for stress/rest SPECT and cardiac MRI. Prior to CT each @entity0 was randomly assigned either to Group A or to Group B in a consecutive order (10 @entity0 per group). Group A underwent @entity3 -stress dynamic real-time myocardial perfusion CT using a novel "shuttle" mode on a 2nd generation dual-source CT. Group B underwent @entity3 -stress first-pass dual-energy myocardial perfusion CT using the same CT scanner in dual-energy mode. Two experienced observers visually analyzed all CT perfusion studies. CT findings were compared with MRI and SPECT. RESULTS: In Group A 149/170 @entity1 (88%) could be evaluated. Real-time perfusion CT (versus SPECT) had 86% (84%) sensitivity, 98% (92%) specificity, 94% (88%) positive predictive value, and 96% (92%) negative predictive value in comparison with perfusion MRI for the detection of myocardial perfusion defects. In Group B all @entity1 were available for analysis. Compared with MRI, dual-energy myocardial perfusion CT (versus SPECT) had 93% (94%) sensitivity, 99% (98%) specificity, 92% (88%) positive predictive value, and 96% (94%) negative predictive value for detecting hypoperfused @entity1 . CONCLUSION: Our results suggest the clinical feasibility of myocardial perfusion CT imaging in @entity0 with acute @entity2 . Compared to MRI and SPECT both, dynamic real-time perfusion CT and first-pass dual-energy perfusion CT showed good agreement for the detection of myocardial perfusion defects.

title: @entity3 -stress dynamic real-time myocardial perfusion CT and @entity3 -stress first-pass dual-energy myocardial perfusion CT for the assessment of acute XXXX : initial results.

answer: @entity2


abstract: PURPOSE: Recent innovations in CT enable the evolution from mere morphologic imaging to dynamic and functional testing. We describe our initial experience performing myocardial stress perfusion CT in a clinical population with acute @entity2 . METHODS AND MATERIALS: Myocardial stress perfusion CT was performed on twenty consecutive @entity0 (15 @entity0 , 5 @entity0 ; mean age 65    8 years) who presented with acute @entity2 and were clinically referred for stress/rest SPECT and cardiac MRI. Prior to CT each @entity0 was randomly assigned either to Group A or to Group B in a consecutive order (10 @entity0 per group). Group A underwent @entity3 -stress dynamic real-time myocardial perfusion CT using a novel "shuttle" mode on a 2nd generation dual-source CT. Group B underwent @entity3 -stress first-pass dual-energy myocardial perfusion CT using the same CT scanner in dual-energy mode. Two experienced observers visually analyzed all CT perfusion studies. CT findings were compared with MRI and SPECT. RESULTS: In Group A 149/170 @entity1 (88%) could be evaluated. Real-time perfusion CT (versus SPECT) had 86% (84%) sensitivity, 98% (92%) specificity, 94% (88%) positive predictive value, and 96% (92%) negative predictive value in comparison with perfusion MRI for the detection of myocardial perfusion defects. In Group B all @entity1 were available for analysis. Compared with MRI, dual-energy myocardial perfusion CT (versus SPECT) had 93% (94%) sensitivity, 99% (98%) specificity, 92% (88%) positive predictive value, and 96% (94%) negative predictive value for detecting hypoperfused @entity1 . CONCLUSION: Our results suggest the clinical feasibility of myocardial perfusion CT imaging in @entity0 with acute @entity2 . Compared to MRI and SPECT both, dynamic real-time perfusion CT and first-pass dual-energy perfusion CT showed good agreement for the detection of myocardial perfusion defects.

title: XXXX -stress dynamic real-time myocardial perfusion CT and @entity3 -stress first-pass dual-energy myocardial perfusion CT for the assessment of acute @entity2 : initial results.

answer: @entity3